Market & Brands
STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
Summary: Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
Adults 21+. WINDBAR does not sell nicotine products on this site. Compliance statement.